Priscilla Driscoll-Shempp
Takeda (United States)(US)Synta Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Coronary Interventions and Diagnostics, Antiplatelet Therapy and Cardiovascular Diseases, Atrial Fibrillation Management and Outcomes, Platelet Disorders and Treatments, Acute Myocardial Infarction Research
Most-Cited Works
- → Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents(2014)1,875 cited
- → Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary Stents(2015)90 cited
- → Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy(2015)55 cited
- → Evaluating the Generalizability of a Large Streamlined Cardiovascular Trial(2014)20 cited
- → Real-World Use of Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe VWD(2023)1 cited
- → LONGITUDINAL SURVEY OF ADULT PATIENTS WITH HEREDITARY ANGIOEDEMA RECEIVING LONG-TERM PROPHYLAXIS WITH LANADELUMAB(2024)
- → Continuous Prophylaxis with Recombinant Von Willebrand Factor in People with Clinically Severe Congenital Types 1 and 2 Von Willebrand Disease in a Real-World Setting: Interim Analysis of Athn 9, a Natural History Study for People with Severe VWD(2024)